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Abstract
Background: We have recently reported that protein phosphate 2A (PP2A) inactivation resulted in increased
phosphorylation of the mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase 1 (JNK1) and
glucocorticoid receptors (GR) at Ser226, thereby reducing GR nuclear translocation and causing corticosteroid
insensitivity in severe asthmatics. Protein tyrosine phosphatases (PTPs) are also known to be critically involved in the
regulation of MAPKs, such as JNK and therefore potentially associated with GR function. The aim of study was to
elucidate the involvement of MAPK-PTPs (PTP-RR, PTP-N5 and PTP-N7), which can dephosphorylate MAPKs, in the
regulation of corticosteroid sensitivity.
Methods: Corticosteroid sensitivity, GR nuclear translocation, phosphorylation levels of GR-Ser226, JNK1 and PP2A
catalytic subunit (PP2AC)-Tyr
307 and protein expression levels and activities of PTP-RR and PP2AC were evaluated in
U937 cells and/or peripheral blood mononuclear cells (PBMCs). Knock-down effects of MAPK-PTPs using siRNA were
also evaluated.
Results: Knock-down of PTP-RR, but not of PTP-N5 or PTP-N7 impaired corticosteroid sensitivity, induced GR-Ser226
phosphorylation and reduced GR nuclear translocation. Under IL-2/IL-4-induced corticosteroid insensitivity, PTP-RR
expression, activity and associations with JNK1 and GR were reduced but PTP-RR activity was restored by
formoterol. Also in PBMCs from severe asthmatic patients, PTP-RR and JNK1 expression were reduced and GR-Ser226
phosphorylation increased. Furthermore, PTP-RR was associated with PP2A. PTP-RR reduction enhanced PP2AC-
Tyr307 phosphorylation leading to impairment of PP2A expression and activity.
Conclusions: We demonstrated that with corticosteroid insensitivity PTP-RR fails to reduce phosphorylation of JNK1
and GR-Ser226, resulting in down-regulation of GR nuclear translocation. Reduced PTP-RR may represent a novel
cause of corticosteroid insensitivity in severe asthmatics.
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Background
Currently most patients with asthma are well controlled
with the regular use of inhaled corticosteroids (ICS) with
or without long-acting β2-adrenoceptor agonists
(LABAs). Even though corticosteroids exert multifaceted
anti-inflammatory effects, they are not disease-modifying
and poorly effective in severe asthmatics who present a
more corticosteroid insensitive phenotype [1]. Hence,
elucidating the molecular mechanisms of corticosteroid
insensitivity could lead a more effective therapeutic ap-
proach for severe asthma.
Defective function of glucocorticoid receptors (GR),
such as decreased nuclear translocation, protein expres-
sion, ligand binding and binding to glucocorticoid-
response elements (GRE) may be involved in corticoster-
oid insensitivity in severe asthma [2]. One possible cause
of impaired GR nuclear translocation is the phosphoryl-
ation of GR by mitogen-activated protein kinases
(MAPKs) [2–5]. In patients with severe asthma in-
creased phosphorylation of GR and subsequent reduced
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nuclear translocation have been reported [2, 5, 6]. How-
ever, the molecular mechanisms of GR phosphorylation
that lead to GR nuclear translocation have not yet been
elucidated. Phosphorylation of Ser203 and Ser211 have
been shown to induce GR activation [7–9] whereas
Ser226 phosphorylation leads to inhibition of GR
function [10–12]. Recently, we found that GR is hyper-
phosphorylated at Ser226 possibly via the action of c-Jun
N-terminal kinase 1 (JNK1) in peripheral blood mono-
nuclear cells (PBMCs) from severe asthmatics and in a
corticosteroid insensitive PBMC model [13]. This is sup-
ported by previous findings that phosphorylation of
Ser226 by JNK contributes to impairment of GR tran-
scriptional activation [11] and GR shuttling [10]. Thus,
GR-Ser226 phosphorylation might be involved in reduc-
tion of GR nuclear translocation.
Protein tyrosine phosphatases (PTPs) which regulate
the level of tyrosine phosphorylation play a critical role
in regulating signaling molecules such as mitogen-
activated protein kinases (MAPKs) [14]. At least 107
PTPs are now recognized and they are classified into
four groups based on the amino acid sequences of their
catalytic domains [15, 16]. Tyrosine-specific classical
PTPs which are classified into class I cysteine-based
PTPs are further divided into two subgroups: receptor-
like transmembrane PTPs; R1-R8 and non-transmembrane
PTPs; NT1-NT9 [14]. The R7, one of receptor-like PTPs
subgroup, termed ‘MAPK-PTPs’, consists of PTP-N5
[also known as striatal-enriched phosphatase (STEP)],
PTP-N7 [also known as hematopoietic PTP (HePTP)]
and PTP-RR [also known as PCPTP1 or STEP-like
PTP (PTP-SL)]. PTP-N5, PTP-N7 and PTP-RR have
all been reported to down-regulate MAPKs [17].
Among dual-specific phosphatases (DUSPs), another
class I cysteine-based PTPs, MAPK phosphatases such
as DUSP1 and DUSP4 are also involved in the regula-
tion of MAPKs [16].
We have recently found that protein phosphatase 2A
(PP2A), a serine/threonine phosphatase, regulates cortico-
steroid sensitivity by dephosphorylation of JNK1 and GR-
Ser226, and PP2A located in the cell membrane/cytoplasm
may be inactivated by phosphorylation of Tyr307 [13, 18],
suggesting that other PTPs may be also involved in the
regulation of corticosteroid sensitivity. We therefore hy-
pothesized that reduction of MAPK-PTPs might also en-
hance JNK1 and GR-Ser226 phosphorylation resulting in
impairment of GR nuclear translocation and corticoster-
oid sensitivity. In this study, we focus on ‘R7 PTPs (PTP-
N5, −N7 and -RR)’, but not other MAPK phoshatases
(DUSPs) which are mainly localized in the nucleus [19],
and show that PTP-RR is down-regulated in PBMCs from
severe asthmatics and in an in vitro corticosteroid insensi-
tive cellular model. In addition, knockdown of PTP-RR
(using siRNA) reduced GR nuclear translocation and
corticosteroid sensitivity concomitantly with enhanced
phosphorylation of JNK1 and GR-Ser226.
Methods
Reagents
3-(4,5-dimethylthiazol-2years)-2–5-diphenyltetrazolium
bromide (MTT), dimethyl sulfoxide (DMSO), ICI-
118551, salmeterol and salbutamol were purchased from
Sigma-Aldrich (Poole, UK). Forskolin, a cAMP inducer
(EC50 = 4 μM) (Calbiochem, Darmstadt, Germany) and
MG-132 (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) were also purchased. Formoterol was obtained
from AstraZeneca R&D Mölndal (Mölndal, Sweden). Re-
combinant human IL-2 and IL-4 were purchased from
R&D Systems Europe (Abingdon, UK). The rabbit
monoclonal antibody (Ab) to PP2A catalytic subunit
(PP2AC), the rabbit polyclonal anti-GR (phospho S
226)
Ab, and the mouse monoclonal Ab to β-actin and TATA
binding protein TBP were obtained from Abcam (Cam-
bridge, UK). The rabbit polyclonal anti-GR Ab, the
mouse monoclonal Ab to PP2AC (phospho Try
307), pro-
tein A/G plus-agarose and α-tubulin were obtained from
Santa Cruz Biotechnology (Heidelberg, Germany). Rabbit
polyclonal anti-phospho-SAPK/JNK and anti-SAPK/JNK
Abs were obtained from Cell Signaling Technology
(Danvers, MA). The rabbit polyclonal anti-PTP-RR Ab
was purchased from Sigma Aldrich (Poole, UK) and Life-
Span BioSciences (Seattle, WA).
Subjects
PBMCs obtained from 10 patients with severe asthma
(SA) [20, 21] and 8 age-matched healthy volunteers
(HV) from the Royal Brompton Hospital (London, UK)
were isolated from whole blood using AccuSPIN
(Sigma–Aldrich). As our previous data showed cortico-
steroid sensitivity in PBMCs from non-severe asthmatics
was normal range [4, 5] without reduction of PP2A ac-
tivity (unpublished data), we focused on the comparison
between HV and SA in this study. Six of 10 subjects in
SA and 5 of 8 subjects in HV were analyzed from sam-
ples used previously [13]. The characteristics of subjects
are shown in Table 1. The severity of asthma was de-
fined by GINA guideline [22]. All patients and healthy
volunteers recruited for this study were never smokers.
This study was approved by the local ethics committee
of Royal Brompton and Harefield NHS Trust
(07_Q0404_31) and written informed consent was ob-
tained from each patient or volunteer.
Cells
The human monocytic cell line U937 was obtained from
the American Type Culture Collection (ATCC, Rock-
ville, MD). Cells were cultured in complete growth
medium (RPMI 1640; Sigma) supplemented with 10 %
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fetal bovine serum (FBS) and 1 % L-glutamine at 37 °C
in a humidified atmosphere with 5 % CO2. Cell viability
was assessed microscopically by trypan blue staining.
Cell lysis, immunoprecipiation, and western blotting
Cell protein extracts were prepared using modified RIPA
buffer (50 mM Tris HCL pH 7.4, 0.5–1.0 % NP-40, 0.25
% Na-deoxycholate, 150 mM NaCl with freshly added
complete protease (Roche, Mannheim, Germany)), as
described previously [13]. Phosphatase inhibitor (Active
Motif, Rixensart, Belgium) and MG-132, a proteasome
inhibitor, were used as needed. Nuclear extraction was
performed using the Nuclear Extraction Active Motif kit
(Active Motif ). Protein concentration was determined
using the Bio-Rad Protein Assay (Bio-Rad). Immunopre-
cipitation was conducted with anti-PTP-RR Ab (Abcam)
or anti-PP2A Ab (Bethyl, Montgomery, TX). Protein ex-
tracts or immunoprecipitates were separated by SDS-
PAGE (Invitrogen, Paisley, UK) and detected by Western
Blot analysis using chemiluminescence (ECL Plus; GE
Healthcare, Chalfont St. Giles, UK). β-actin expression
was used as a control for protein loading as needed.
Corticosteroid sensitivity
Cells were treated with dexamethasone (10−6 M or 10−11
M) for 45 min, followed by TNFα (10 ng/ml) stimulation
overnight. The ability of dexamethasone to inhibit
TNFα-induced CXCL8 release was determined in cell
medium by sandwich ELISA according to the manufac-
turer’s instructions (R&D Systems Europe). IC50 values
for dexamethasone on CXCL8 release were calculated
using the computer program Prism 4.0 (GraphPad Soft-
ware Inc., San Diego, CA) and were used as a marker for
steroid sensitivity (Dex-IC50).
Glucocorticoid receptor nuclear translocation
Cells were treated with dexamethasone (10−7 M) for 1 h.
Nuclear and cytoplasmic GR were measured by Western
Blot. TATA-binding protein (TBP) (for nuclear protein)
or α-tubulin (for cytoplasmic protein) expression was
used as a control for protein loading. The ratio of nu-
clear GR to TBP was used as an index of GR nuclear
translocation.
Protein phosphatase activity
Phosphatase activity was assayed by using the Senso-
Lyte™ MFP Protein Phosphatase Assay Kit (AnaSpec,
San Jose, CA) [13]. Immunopurified PTP-RR or PP2A
were added into assay buffer (20 mM Tris–HCl pH 7.4,
100 mM NaCl, 1 mM EDTA, 1 mM DTT for PTP-RR;
40 mM Tris HCl pH 8.4, 34 mM MgCl2, 4 mM EDTA, 4
mM DTT for PP2A) and incubated with 3-O-
methylfluorescein phosphate (MFP). Phosphatase activity
was measured as a phosphatase-induced dephosphoryla-
tion which was monitored by measuring the
fluorescence of MFP product. PTP-RR or PP2A immu-
noprecipitates were equally divided into two parts, with
half used for phosphatase assay and the other half for
target protein detection by Western Blot analysis. Phos-
phatase activity was normalized to the protein expres-
sion level calculated as band-density.
RNA interference
PTP-N5, PTP-N7, PTP-RR and PP2ACα siRNAs and
non-silencing scrambled control siRNA were purchased
from QIAGEN (Crawley, UK). The siRNA sequences
(0.5 μM) were transfected using an HVJ Envelope (HVJ-
E) Vector Kit GenomONE-Neo (Ishikawa Sangyo Kaisha
Ltd., Osaka, Japan) as described previously [13].
Statistical analysis
Comparisons of two groups of data were performed
using Mann–Whitney U test or paired t-test. Pearson’s
or Spearman’s correlation coefficients were also calcu-
lated. Other data were analyzed by ANOVA with post
hoc test adjusted for multiple comparisons (Bonferroni
test or Newman-Keuls test), as appropriate. The differ-
ence was considered statistically significant if P < 0.05.
Descriptive statistics were expressed as the mean ± SEM.
Results
PTP-RR reduction causes corticosteroid insensitivity
We first examined whether MAPK-PTPs (PTP-N5, PTP-
N7 and PTP-RR) were involved in corticosteroid insensi-
tivity in U937 cells. Western blotting analysis confirmed
30 % knockdown (KD) of PTP-RR, PTP-N5 and PTP-N7
in U937 cells and cell viabilities were more than 70 %
(data not shown). Knockdown (KD) by siRNA of PTP-
RR, but not of PTP-N5 or PTP-N7, resulted in reduction
of dexamethasone inhibition of TNFα-induced CXCL8
release (left panel in Fig. 1a). This was further confirmed
by a significant reduction in dexamethasone IC50 of
Table 1 Characteristics Of Subjects
Healthy volunteers
(n = 8)
Severe asthmatics
(n = 10)
Gender (M:F) 2:6 4:6
Age 49.9 ± 3.2 53.2 ± 4.9
FEV1.0 %pred. 90.7 ± 3.5 71.7 ± 5.6
FEV1.0/FVC 78.1 ± 1.5 69.1 ± 2.5
ICS none 10/10
(mean dose) a640 ± 72 μg
Oral prednisolone none 6/10
(mean dose) 10.5 ± 3.0 mg
LABA none 10/10
ICS inhaled corticosteroid, a fluticasone propionate equivalent dose, LABA:
long-acting β2-agonist
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315.0 ± 13.4 nM in PTP-RR KD vs. 76.9 ± 5.5 nM in
scrambled RNA control (right panel in Fig. 1a). Support-
ing these findings, PTP-RR KD, but not PTP-N5 KD or
PTP-N7 KD, reduced dexamethasone-mediated GR nu-
clear translocation (Fig. 1b (i) and (ii)), together with an
increase in phosphorylation of GR-Ser226, a biomarker of
GR inactivation (Fig. 1c). Although all three MAPK-
PTPs KDs increased JNK1 phosphorylation (Fig. 1d),
only PTP-RR KD was associated with GR-Ser226 hyper-
phosphorylation (Fig. 1c).
PTP-RR is down-regulated and dissociates from GR/JNK1
complex in corticosteroid insensitive cellular model
Immunoprecipitation of PTP-RR revealed that PTP-RR
is associated with GR and JNK1, suggesting a possible
role of this phosphatase in the function of corticosteroid
dynamics [13, 18] (Fig. 2a). To further confirm the in-
volvement of PTP-RR in corticosteroid insensitivity, we
evaluated PTP-RR function with induced corticosteroid
insensitivity. As showed previously [2, 23], co-
stimulation of U937 cells with IL-2 (20 ng/ml) and IL-4
(10 ng/ml) (IL-2/IL-4) for 48 h induces corticosteroid
insensitivity [4, 13]. Interestingly, IL-2/IL-4 reduced both
PTP-RR protein expression and activity (Fig. 2b and c).
In addition, IL-2/IL-4 dissociated PTP-RR from GR and
JNK1 as shown by co-immunoprecipitation (Fig. 2d and
e). Co-treatment with MG-132 (0.1 μM), a proteasome
inhibitor, prevented IL-2/IL-4-induced PTP-RR reduc-
tion (Fig. 2f ), suggesting that PTP-RR reduction via IL-
2/IL-4-mediated degradation contributes, at least in part,
to corticosteroid insensitivity.
PTP-RR regulates PP2A function
Co-immunoprecipitation studies showed that PTP-RR is
also associated with PP2A, suggesting a possible role of
PTP-RR in the regulation of corticosteroid sensitivity by
dephosphorylation of JNK1 and GR-Ser226 as shown pre-
viously for PP2A [13]. In fact, the association between
PTP-RR and PP2A was reduced by 48 % after co-
stimulation with IL-2/IL-4 (Fig. 3a). Additionally, PTP-
RR KD enhanced PP2A catalytic subunit (PP2AC)-Tyr
307
phosphorylation (Fig. 3b), which is required for down-
regulation of PP2A activity [24]. In addition, reduced
PP2A activity and protein expression were observed
Fig. 1 Effects of PTP-RR knockdown by siRNA. U937 cells were transfected with scramble control (SC), PTP-N5 (N5), PTP-N7 (N7) and PTP-RR (RR)
siRNAs. a The ability of dexamethasone (Dex) to inhibit TNFα-induced IL-8 release was expressed as % inhibition by Dex (left panel) or Dex-IC50
(right panel). b GR nuclear translocation indicated as the ratio of nuclear GR to TBP (SC vs. RR siRNA in (i) and SC vs. N5 and N7 in (ii)). c, d,
Phosphorylation levels of GR-Ser226 (c) and JNK1 (d). Data in c and d are expressed as fold change against SC. Values represent means of three
(a and d) or four (b and c) experiments ± SEM: # P < .05, ## P < .01 (vs. SC or NT in each group), ** P < .01 (as shown between two groups)
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after PTP-RR KD (Fig. 3c and d). On the other hand,
PP2A KD did not change PTP-RR activity or expression
(Fig. 3e and f).
PTP-RR is reduced in PBMCs from severe asthmatics
Consistent with the IL-2/IL-4-induced corticosteroid in-
sensitive U937 model, PTP-RR expression in PBMCs
from severe asthmatics was significantly lower than
those from healthy volunteers (Fig. 4a). In line with the
findings observed in PTP-RR KD study, PTP-RR
expression levels in PBMCs from severe asthmatics and
healthy volunteers negatively correlated with phosphor-
ylation levels of PP2AC-Tyr
307 and positively correlated
with PP2A activity and expression (panel (i) to (iii) in
Fig. 4b). Previously, we have shown that GR from severe
asthmatic patients is hyperphosphorylated at Ser226 and
associated with increased JNK1 phosphorylation [13].
Interestingly, we found in the present study that PTP-
RR expression levels in PBMCs were negatively corre-
lated with phosphorylation levels of GR-Ser226 and
Fig. 2 PTP-RR function under corticosteroid insensitive condition. a GR and JNK1 expression in PTP-RR-immunoprecipitates. b, c, d, e, f, U937 cells
were exposed to IL-2/IL-4 for 48 h. PTP-RR protein expression (b) and activity (c) in whole cell extracts. GR (d) and JNK1 (e) protein expressions in
PTP-RR-immunoprecipitates. Effect of MG-132 on PTP-RR expression (f). Data in (d) and (e) are expressed as fold change against non-treatment
control (NT). Values represent means of four experiments ± SEM. # P < .05, ## P < .01 (vs. NT) and ** P < .01 (as shown between two groups)
Fig. 3 Regulation of PP2A by PTP-RR. a U937 cells exposed to IL-2/IL-4 for 48 h (or were not treated; NT). PP2AC was detected in PTP-RR-
immunoprecipitates. b, c, d, PP2AC-Tyr
307 phosphorylation (b), PP2A activity (c) and PP2AC protein expression (d) were analyzed in U937 cells
transfected with scramble control (SC) or PTP-RR siRNAs. e, f, In U937 cells transfected with scramble control (SC) or PP2A siRNAs, immunopurified PTP-
RR activity (e) and PTP-RR protein expression (f) were analyzed. Data in (f) is expressed as fold change against SC. Values represent means of four (a, d
and f) or three (b, c and e) experiments ± SEM. # P < .05, ## P < .01 (vs. non-treatment control; NT or SC)
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JNK1, suggesting an association between PTP-RR and
the GR/JNK1 complex (panel (iv) and (v) in Fig. 4b). Re-
garding PTP-RR activity in PBMCs, we could not collect
enough samples from patients because a lot of PBMCs
were needed to detect the phosphatase activity in IP-
PTP-RR. We confirmed that co-stimulation with IL-2/
IL-4 reduced IP-PTP-RR activity in PBMCs from healthy
volunteers (by up to 30 %) as observed in U937 cells
(data not shown).
PTP-RR is activated by formoterol
We have previously shown that a LABA, formoterol, re-
stores corticosteroid sensitivity in severe asthmatics via
restoration of PP2A activity [18]. Interestingly, formoterol
also significantly enhanced PTP-RR activity (more than 2-
fold at the concentrations of 10−9 to 10−7 M) (Fig. 5a).
Furthermore, formoterol (10−9 M) completely reversed IL-
2/IL-4-induced reduction of PTP-RR activity (Fig. 5b).
These findings are supported by our previous study in
which formoterol (10−9 M) restored corticosteroid sensi-
tivity with submaximal effect (90 %) in the presence of IL-
2/IL-4 [18]. Formoterol-mediated PTP-RR activation was
not inhibited by a selective β2-adrenoceptor antagonist
(ICI-118551), and PTP-RR activity was not enhanced by
cAMP inducer, forskolin. The appropriate concentration
of ICI-118551 (10−5 M) was determined by its inhibitory
effect on formoterol-induced cAMP production (more
than 90 %) [18]. In addition, PTP-RR was activated to a
higher extent by formoterol (10−9 M) than by salmeterol
(10−7 M), while salbutamol (10−7 M) had no effect (Fig. 5a
and c). Importantly, this results denoted the same ten-
dency as previous findings that formoterol (10−9 M) re-
stored corticosteroid sensitivity in severe asthmatics with
higher extent compared to salmeterol (10−7 M) [5]. Taken
together, it seems that PTP-RR is activated by LABAs
(especially formoterol) in a β2-adrenoceptor-independent
fashion as recently reported with PP2A [18] and that
PTP-RR regulates PP2A function.
Fig. 4 PTP-RR protein expression and its association with PP2A function and phosphorylation levels of GR and JNK1 in PBMCs. a PTP-RR
expression in PBMCs from healthy volunteers (HV) and severe asthmatics (SA). Individual values and means of eight (HV) and ten (SA) subjects are
shown. ## P < .01 (vs. HV). b Correlation between PTP-RR protein expression and PP2AC-Tyr
307 phosphorylation (i), IP-PP2A activity (ii), PP2AC
protein expression (iii), phosphorylation of GR-Ser226 (iv) and JNK1 (v) in PBMCs. Individual values (HV and SA) are shown and the dotted lines
indicate 95% confidence interval
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Discussion
Our study has revealed a novel role for PTP-RR in the
regulation of corticosteroid sensitivity by modulating GR
nuclear translocation after corticosteroid treatment. Im-
portantly, we confirmed that PTP-RR is down-regulated
in PBMCs from severe asthmatics and in an in vitro
corticosteroid insensitive cellular model induced by co-
stimulation with IL-2/IL-4. In this model, PTP-RR was
dissociated from GR/JNK1 complex leading to hyper-
phosphorylation of JNK1 and GR-Ser226. In addition, we
found that impaired PTP-RR causes down-regulation of
PP2A, which is also involved in JNK1 and GR-Ser226
phosphorylation by favoring of PP2AC-Tyr
307 phosphor-
ylation. Thus, it seems that PTP-RR might regulate cor-
ticosteroid sensitivity both directly and indirectly via
modulation of PP2A activity (Fig. 6).
Reduction of GR nuclear translocation is one of causes
of corticosteroid insensitivity in severe asthma [2, 4]. In
fact, dexamethasone-induced translocation of GR into
the nucleus is reduced in PBMCs from patients with
Fig. 5 Effect of formoterol on immunopurified PTP-RR activity in U937 cells. a Cells were treated with formoterol (FM; 10−10-10−7 M), salmeterol
(SM; 10−7 M) or salbutamol (SB; 10−7 M) for 20 min. b Cells stimulated with IL-2/IL-4 for 48 h were treated with FM (10−9 M) for 20 min. c Cells
were preincubated with or without ICI-118551 (ICI; 10−5 M), a selective β2-adrenoceptor antagonist for 30 min, followed by treatment with FM (10−9 M) or
cAMP inducer, forskolin (10−5 M). Data are expressed as fold change against non-treatment control (NT). Values represent means of four (a and b) or three
(c) experiments ± SEM: # P< .05, ## P< .01 (vs. NT), and ** P< .01 (as shown between two groups)
Fig. 6 Proposal mechanism of regulation of corticosteroid sensitivity. Reduction of GR nuclear translocation by phosphorylation of GR-Ser226 is
one of key mechanisms of corticosteroid insensitivity. Severe allergic inflammation associated with production of IL-2 and IL-4 (white arrows)
induces phosphorylation of GR-Ser226 by JNK1 activation and PP2A inactivation (Tyr307 phosphorylation). PTP-RR regulates corticosteroid sensitivity
by dephosphorylation of JNK1/GR-Ser226 directly and/or indirectly via PP2A
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severe asthma and this correlates with other indices of
defective corticosteroid sensitivity in these patients [6].
Also in IL-2/IL-4-induced corticosteroid insensitive
model, reduced GR nuclear translocation has been re-
ported [4, 23]. We demonstrated that knocking-down
PTP-RR reduces GR nuclear translocation with con-
comitant induction of corticosteroid insensitivity, and
that PTP-RR expression was reduced in severe asthma
and in the IL-2/IL-4-induced corticosteroid insensitive
model. Our results suggest that PTP-RR might be a key
molecule involved in the regulation of GR nuclear trans-
location in severe asthma.
Inhibition of PTP-RR by knockdown and co-
immunoprecipitation studies indicated that PTP-RR is
present in a GR/JNK1 complex and associated with de-
phosphorylation of GR-Ser226 and JNK1. We also exam-
ined the involvement of other MAPK-PTPs, PTP-N5
and PTP-N7 in phosphorylation of JNK1 and GR-Ser226.
In U937 cells that were knocked down for PTP-N5 or
PTP-N7, the phosphorylation levels of JNK1 were also
enhanced, however neither PTP-N5 nor PTP-N7 knock-
downs increased GR-Ser226 phosphorylation. SP600125,
a JNK inhibitor partially reduced phosphorylation of
GR-Ser226 in IL-2/IL-4-induced corticosteroid insensitive
model [18], suggesting that other signals (kinases and/or
phosphatases) may be involved in PTP-RR-mediated
regulation of GR-Ser226 phosphorylation.
It has been reported that PTP-RR inactivates extracel-
lular signal-regulated kinase (ERK)1/2 by dephosphoryla-
tion of tyrosine residues [25] and that PTP-RR
associates with ERK1/2 and p38 through a kinase inter-
action motif (KIM) required for phosphorylation of
PTP-RR by these kinases [26]. However, it was not previ-
ously established whether PTP-RR could dephosphory-
late JNK1. We have recently found that a serine/
threonine phosphatase, protein phosphatase 2A (PP2A)
also dephosphorylates JNK1 and GR-Ser226 [13]. As we
have shown an association between PTP-RR and PP2A
(Fig. 3a), PTP-RR might dephosphorylate JNK1 and GR-
Ser226 in collaboration with PP2A. Another possibility is
that PTP-RR indirectly regulates phosphorylation levels
of JNK1 and GR-Ser226 via PP2A. PP2A catalytic sub-
unit, a regulator of PP2A complexes and activity [27], is
phosphorylated at Tyr307 residue [28], resulting in reduc-
tion of PP2A activity [24]. We confirmed that increased
phosphorylation of PP2AC-Tyr
307 after knockdown of
PTP-RR, but not of PTP-N5 and PTP-N7 leads to a de-
crease in PP2A activity (Fig. 3b, c, and Additional file 1:
Figure S1). On the other hand, PP2A knockdown did
not affect PTP-RR activity, expression (Fig. 3e and f)
and association with JNK1 (data not shown), suggesting
that PTP-RR could be associated with JNK1, independ-
ently of PP2A. Thus, PTP-RR, but not PTP-N5 and
PTP-N7 regulates dephosphorylation of JNK1 and GR-
Ser226 directly and/or indirectly via PP2A. Regarding the
mechanism of PTP-RR down-regulation, MG-132, a pro-
teasome inhibitor, abrogated IL-2/IL-4-induced reduc-
tion of PTP-RR protein expression, suggesting that a
reduction in PTP-RR protein stability in severe asthma
could be taking place. Recently, several studies demon-
strated Tyr307 phosphorylation of PP2A is regulated via
protein tyrosine phosphatase 1B (PTP1B) [29, 30]. To-
gether with our findings, the conclusion can be drawn
that several phosphatases with the ability to dephosphor-
ylate tyrosine residues might control cellular functions
in collaboration with PP2A.
PTP-RR is expressed predominantly in brain, and regu-
lates cerebellar neurons and motor coordination [31]. In
addition, PTP-RR has been also detected in other non-
neuronal tissues, such as cartilage and intestinal mucosa,
and regulates bone morphogenesis and tumor genesis, re-
spectively [32, 33]. Importantly, it seems that PTP-RR
negatively regulates tumor progression in neoplastic disor-
ders such as cervical cancer or colorectal cancer [32, 34].
We have revealed for the first time that PTP-RR is also
expressed in PBMCs and the U937 human monocytic cell
line, and shows reduced expression in severe asthma and
IL-2/IL-4-induced corticosteroid insensitivity, respectively.
This suggests that PTP-RR might be a potential novel
therapeutic target for various diseases with reduced cor-
ticosteroid sensitivity including severe asthma. PTP-RR
was activated by formoterol although this effect was inde-
pendent of the β2-adrenoceptor function. We have previ-
ously observed that formoterol was able to restore PP2A
activity independently of β2-adrenoceptor, however the
mechanism of action remains unknown [18]. Further-
more, as LABAs are reported to provide beneficial effects
in exacerbation of allergic airway disease by activating
PP2A [35], PTP-RR activation by LABAs may also con-
tribute to their beneficial effects on asthma control.
Conclusions
We have reported for the first time that PTP-RR is re-
duced in severe asthmatics and that in corticosteroid in-
sensitive condition, impaired PTP-RR causes
phosphorylation of JNK1 and GR-Ser226 directly and/or
indirectly via PP2A, resulting in less corticosteroid-
induced nuclear translocation of GR. Thus, PTP-RR is a
novel therapeutic target for the restoration of corticoster-
oid sensitivity in severe asthma.
Additional file
Additional file 1: Figure S1. Effect of PTP-N5 and PTP-N7 knock-down
on regulation of PP2A. A, B, PP2AC-Tyr
307 phosphorylation (A) and PP2A
activity (B) were analyzed in U937 cells transfected with scramble control
(SC), PTP-N5 (N5) and PTP-N7 (N7) siRNAs. Values represent means of
three experiments ± SEM. (JPG 30 kb)
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